Increasing Incidence of Lentigo Maligna Melanoma Subtypes: Northern California and National Trends 1990–2000

Stanford University, Palo Alto, California, United States
Journal of Investigative Dermatology (Impact Factor: 7.22). 10/2005; 125(4):685-91. DOI: 10.1111/j.0022-202X.2005.23852.x
Source: PubMed


Worldwide, lentigo maligna melanoma (LMM) comprises 4%-15% of cutaneous melanoma and occurs less commonly than superficial spreading or nodular subtypes. We assessed the incidence of melanoma subtypes in regional and national Surveillance, Epidemiology, and End Results (SEER) cancer registry data from 1990 to 2000. Because 30%-50% of SEER data were not classified by histogenetic type, we compared the observed SEER trends with an age-matched population of 1024 cases from Stanford University Medical Center (SUMC) (1995-2000). SEER data revealed lentigo maligna (LM) as the most prevalent in situ subtype (79%-83%), and that LMM has been increasing at a higher rate compared with other subtypes and to all invasive melanoma combined for patients aged 45-64 and > or =65 y. The SUMC data demonstrated LM and LMM as the only subtypes increasing in incidence over the study period. In both groups, LM comprised > or =75% of in situ melanoma and LMM > or =27% of invasive melanoma in men 65 y and older. Regional and national SEER data suggest an increasing incidence of LM and LMM, particularly in men > or =age 65. An increased incidence of LM subtypes should direct melanoma screening to heavily sun-exposed sites, where these subtypes predominate.

Full-text preview

Available from:
  • Source
    • "In South Africa, its rates vary between 0.5 and 1.8 cases per year per 100,000 population among black Africans against 4.4 to 6.2 per 100,000 per year in whites people[17]. It has been shown that advancing age is a pejorative factor independent of other prognostic factors for melanoma usually accepted[18]. It is however unclear whether this fact is due to a particular biological behavior of melanoma that develop in the aged individual with reduced immune defenses of the host, or both[17]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Background: The elderly cancers are worldwide a major public health issue. Their exact incidence is unknown in Togo. The purpose of this study was to describe epidemiological and histological data of cancers in the elderly in Togo. Materials and Methods: This was a cross-sectional and descriptive study of cases of elderly cancers diagnosed at the laboratory of pathology of the university teaching hospital of Lomé from 1995 to 2014 (20 years). Cases of examination on samples of the elderly (biopsy, excision, surgical specimens) were collected from the data records of that laboratory. Results: Overall, 792/5200 cases of elderly cancer were collected representing 15.2% of all cancers diagnosed in the laboratory. The annual incidence was 39.6 cases. Patient age ranged from 65 to 103 years old, with a mean of 68.5 ± 4 years old. The sex ratio (M/F) was 1.3. At pathological level, the study material included pieces (n=290 cases; 36.6%) and biopsies (n=502 cases; 63.4%). Cancers located preferably in prostate in men (38%), and in women the most frequent locations were cervix (16.2%) and breast (15.8%). We noticed four histological groups: carcinomas (n = 706 cases; 89.1%), sarcomas (n = 43 cases; 5.5%), lymphoma (n = 34 cases; 4.3%) and melanoma (n = 9 cases; 1.1%). Carcinomas were dominated by adenocarcinomas (50.1%) and squamous cell carcinomas (33.8%); Kaposi’s sarcoma (32.6%) was the most common histological type in sarcomas. Conclusion: Our results showed that the elderly cancers were frequent in Togo, locating mostly in uterus cervix and breast in female, and prostate in men. This study could help to advocate the establishment of a cancer registry in Togo. Keywords Cancer, Elderly, Togo
    Full-text · Article · Jan 2016 · Open Journal of Pathology
  • Source
    • "The frequency of occurrence of the less common cutaneous malignancies such as cutaneous B-cell and T-cell lymphomas , soft tissue sarcomas (for example, dermatofibrosarcoma protuberans (DFSP)), sebaceous carcinoma, and Merkel cell carcinoma is poorly documented. The studies that mention the incidence rates of these rare skin malignancies are mainly using data from the Surveillance, Epidemiology and End Results (SEER) program, which registers pathology reports of nine areas that cover about 10% of the US population (Swetter et al., 2005; Morton et al., 2006; Criscione and Weinstock, 2007; Rouhani et al., 2008; Bradford et al., 2009). Currently, there are over 16.5 million Dutch citizens, of whom the majority is white. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Epidemiology of rare cutaneous malignancies in the general population is poorly documented. This descriptive study aimed to estimate the incidence and trends of all skin malignancies between 1989 and 2005. Data on skin tumors were extracted from the Netherlands Cancer registry (except for basal cell carcinoma (BCC) data-only available from Comprehensive Cancer Centre South) and categorized according to the International Classification of Diseases for Oncology, third edition, codes. Age-standardized incidence rates (European standardized population rate, ESR) per 100,000 person-years were calculated per year and for the period between 2001 and 2005. Estimated annual percentage changes (EAPCs) were estimated by Poisson regression models. A total of 356,620 skin tumors were diagnosed between 1989 and 2005. Excluding BCC, squamous cell carcinoma (SCC), and melanoma, the remaining skin tumors constituted about 2% of all skin malignancies. The incidence of melanoma showed the steepest increase (EAPC, 4.0%), and ESR was close to that observed for SCC (EAPC, 2.3%) between 2001 and 2005 (17.1 versus 19.6). Hematolymphoid tumors (ESR=0.74) were mainly cutaneous T-cell lymphomas (60.8%). No significant increases in incidence were observed for lymphomas, and appendageal, fibromatous, and myomatous carcinomas during 1989-2005. In addition to keratinocytic cancers and melanoma, there is a wide variety of skin tumors that constitute <2% of all skin malignancies. The incidence of UV-related skin tumors increased significantly and more steeply than did those of other skin malignancies.
    Full-text · Article · Mar 2010 · Journal of Investigative Dermatology
  • Source
    • "Cutaneous melanoma is a cause of concern for those involved in cancer control in Europe (de Vries et al, 2003; Hemminki et al, 2003; de Vries and Coebergh, 2004), North America (Jemal et al, 2001; Swetter et al, 2005), and Australasia (Martin and Robinson, 2004; Baade and Coory, 2005; Coory et al, 2006). Data from all three continents show a continuing rise in incidence, although in some countries incidence figures may be stabilising in younger females. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We studied 12,450 cases of invasive melanoma diagnosed in Scotland in 1979-2003, by thickness, pathological type, and body site at ages under 40, 40-59, and 60 years and over. Melanoma incidence trebled in males from 3.57 to 10.93/10(5) per year, and increased 2.3-fold in females from 5.60 to 12.96/10(5) per year. The rate of increase fell in each successive 5-year period. The greatest increase was in males aged 60 years and over at diagnosis. Significant incidence increases were seen in melanomas < 1 mm in all three age groups, but those > 4 mm only increased significantly at ages 60 years and over. All histological types increased significantly at ages 60 years and over, and in this age group the greatest increase was seen on the head and neck. Five-year disease-free survival improved steadily. Survival figures for 1994-1998 ranged from 93.6% for males and 95.8% for females with tumours < 1 mm, to 52.4 and 48.3%, respectively, for those with tumours > 4 mm. Over the 25 years, melanoma mortality doubled in males from 1.1 to 2.4/10(5) per year, but was unchanged in females at 1.5/10(5) per year. Public education on melanoma is required both for primary prevention and earlier diagnosis, particularly for older males.
    Full-text · Article · Jun 2007 · British Journal of Cancer
Show more